Mutant ras peptide vaccine - GlaxoSmithKline
Latest Information Update: 31 Dec 2021
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Pancreatic cancer
Most Recent Events
- 06 Sep 2006 Discontinued - Phase-II for Colorectal cancer in USA (SC)
- 06 Sep 2006 Discontinued - Phase-II for Pancreatic cancer in USA (SC)
- 07 Jul 2003 Phase-II clinical trials in Colorectal cancer in USA (SC)